I sit down with Dr. Metasebya Solomon and Louis Jefferson to discuss the incomplete science behind Pfizer and Biogen’s supposed “vaccine”. Subscribe to our YouTube channel by CLICKING HERE.
Dr. Metasebya Solomon: an accomplished research scientist with 10+ years of experience in biomedical research and development. Dr. Solomon is the Director of Research Design and Programming bridging her deep understanding of academic research with the healthcare research industry. She leads the strategic engagement with our academic and industry research collaborators for meaningful outcomes in Sickle Cell Disease research. Dr. Solomon’s goal is to contribute to biomedical research that focuses on the targeted development of essential medical technologies. Her aim is to achieve this by bringing the influences of real-world evidence in design solutions to improve treatment effects and outcomes. Ultimately, she seeks to develop treatments to help each individual achieve their full health and human potential. She earned her Ph.D. in Biomedical Engineering from Washington University in St. Louis and B.S. from the University of Texas at Austin in Biomedical Engineering with digital applications focus.
Louis Jefferson: medical training at the University of Toledo, School of Medicine and graduate education at the University of Pittsburgh Graduate School of Public Health as well as the University of Connecticut, School of Pharmacy has been instrumental in developing his multidisciplinary approach to clinical research, pharmacology, and medicine. This includes pharmacological studies of G-protein coupled receptors, signal transduction mechanisms, and immunohistochemistry to identify and answer scientific questions related to the development of monoclonal antibodies to treat sickle cell disease as well as other rare and chronic diseases. For 20+ years, Louis has provided global senior leadership in clinical research development for big pharma companies. His therapeutic areas of expertise of drug and biologics discovery include infectious disease, oncology, CNS, pain management, assay development, gastrointestinal disorders, rare diseases, nephrology and hematology. Louis’ long-term goal is to lead independent research programs focused on the development of viable advanced non-invasive medical solutions for the medically underserved.